[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576068":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":17,"locations":24,"responsibleParty":37,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",null,[9,13],{"name":10,"affiliation":11,"role":12},"Astrid Blom, MD","Dermato-oncology Department, Ambroise Paré Hospital, APHP","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":15,"role":16},"Yassine Taoufik, MD, PhD","U1186 INSERM, PAUL BROUSSE Hospital, APHP","STUDY_DIRECTOR",[18,22],{"name":10,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+33 (01) 49 09 44 82","astrid.blom@aphp.fr",{"name":14,"role":19,"phone":7,"phoneExt":7,"email":23},"yassine.taoufik@aphp.fr",[25],{"facility":11,"status":26,"city":27,"state":7,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":7},"RECRUITING","Boulogne-Billancourt","92100","France","FR",{"type":32,"coordinates":33},"Point",[34,35],2.24128,48.83545,{"lat":35,"lon":34},{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[40],{"name":41,"class":42},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV","100576068","validation-of-in-vitro-method-for-anti-mcpyv-immunotherapy-on-patients-with-cutaneous-merkel-cell-carcinoma-100576068",false,"NCT06780475","Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma","Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin","VIRASKIN","Inclusion Criteria:\n\n* Patients \\>= 18 years old;\n* Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;\n* Informed for the study and no-opposed for participation;\n* Affiliated with a social security scheme or in an equivalent situation.\n\nExclusion Criteria:\n\n* Patients ongoing another interventional clinical trial;\n* Patients under guardianship or trusteeship;\n* Pregnancy or breastfeed;\n* Patients refusal.","ALL","18 Years",{"count":54,"type":55},15,"ESTIMATED","OBSERVATIONAL","The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.",[59],"Merkel Cell Carcinoma of Skin",[59],"2025-11-18",{"date":63,"type":64},"2025-11-19","ACTUAL",{"date":66,"type":64},"2025-05-27",{"date":68,"type":55},"2027-05",{"name":5,"class":6},1]